
The FDA approved giredestrant plus everolimus in ESR1-mutated breast cancer and neladalkib in ALK+ NSCLC, issued a CRL to ivonescimab, and more.
This article discusses the current treatment landscape and therapeutic strategies for relapse/refractory diffuse large B-cell lymphoma (R/R DLBCL), the role of CAR T-cell therapies in R/R DLBCL, and insights on new regimens and ongoing clinical trials from leading experts in hematologic malignancies.





